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Abstract
Purpose: To examine the frequency and potential of dose-volume predictors for chest wall (CW) toxicity (pain and/or rib
fracture) for patients receiving lung stereotactic body radiotherapy (SBRT) using treatment planning methods to minimize
CW dose and a risk-adapted fractionation scheme.
Methods: We reviewed data from 72 treatment plans, from 69 lung SBRT patients with at least one year of follow-up or CW
toxicity, who were treated at our center between 2010 and 2013. Treatment plans were optimized to reduce CW dose and
patients received a risk-adapted fractionation of 18 Gy63 fractions (54 Gy total) if the CW V30 was less than 30 mL or 10–
12 Gy65 fractions (50–60 Gy total) otherwise. The association between CW toxicity and patient characteristics, treatment
parameters and dose metrics, including biologically equivalent dose, were analyzed using logistic regression.
Results: With a median follow-up of 20 months, 6 (8.3%) patients developed CW pain including three (4.2%) grade 1, two
(2.8%) grade 2 and one (1.4%) grade 3. Five (6.9%) patients developed rib fractures, one of which was symptomatic. No
significant associations between CW toxicity and patient and dosimetric variables were identified on univariate nor
multivariate analysis.
Conclusions: Optimization of treatment plans to reduce CW dose and a risk-adapted fractionation strategy of three or five
fractions based on the CW V30 resulted in a low incidence of CW toxicity. Under these conditions, none of the patient
characteristics or dose metrics we examined appeared to be predictive of CW pain.
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Introduction
Stereotactic body radiation therapy (SBRT) has emerged as an
excellent alternative to surgical resection for patients with
medically inoperable early stage non-small cell lung cancer
(NSCLC) or oligometastatic lesions to the lung. SBRT is a
treatment technique that delivers highly conformal, high dose
radiation, with a hypofractionated scheme (e.g. 18 Gray63
fractions), which is drastically different from conventionally
fractionated radiation therapy (RT) which employs daily doses of
,2 Gray per fraction delivered over several weeks.
Numerous single-institutional series [1–3] and phase II studies
[4–6], including a multi-institutional Radiation Therapy Oncology
Group (RTOG) study, have demonstrated high local control rates
of greater than 80–90% with SBRT for lung tumors and a low risk
of severe toxicity (,10%) when patients are appropriately selected.
However, early reports of lung SBRT demonstrated unique
toxicity events that have not been previously seen with conven-
tionally fractionated thoracic RT. In particular, chest wall (CW)
toxicity, which typically occurs several months after SBRT, has
been observed in multiple series with varying incidences [7–16].
CW toxicity includes a spectrum of clinical findings including rib
fracture (symptomatic or asymptomatic), CW pain (focal or diffuse)
PLOS ONE | www.plosone.org 1 April 2014 | Volume 9 | Issue 4 | e94859or skin changes (erythema, ulceration). These early series
evaluating SBRT toxicity defined the CW as an organ at risk
(OAR).
One of the earliest CW toxicity publications, Dunlap et al [7],
determined that the volume of CW receiving at least 30 Gy (V30)
was associated with CW toxicity and that maintaining the CW
(CW) V30 below 30 mL resulted in a trend toward reduced
toxicity. Similarly, a series from Stephans et al [8] demonstrated a
correlation between tumor size and CW dosimetry with CW
toxicity and concluded that maintaining two dosimetric parame-
ters for the CW, V30,30 mL and V60,3 mL, resulted in a lower
(10–15%) risk of CW toxicity. In addition, Woody et al [9]
employed the concept of modified equivalent dose (mEUD) [17]
and concluded for their series, that mEUD was a better predictor
of CW pain than V30.
Based on these early reports of CW toxicity, starting in 2010 we
modified our departmental lung SBRT regimen to a risk-adapted
fractionation approach [10], based primarily on the CW V30.
With the goal of significantly reducing CW toxicity after
treatment, peripheral tumors with minimal CW contact and CW
V30#30 ml were treated with 18 Gy63 fractions (54 Gy total)
while peripheral tumors with broad CW contact and/or CW
V30.30 mL were treated with 10–12 Gy65 fractions (50–60 Gy
total).
In this study, we report the incidence of CW toxicity for patients
treated with a risk-adapted SBRT approach based on CW
dosimetry (V30). Also, we present a comprehensive analysis to
identify other metrics that might further predict CW toxicity in
these patients.
Methods and Materials
Patient selection and evaluation
This study was conducted with the approval of the institutional
review board (IRB) for the Dana-Farber/Brigham and Women’s
cancer center. Because our study was a retrospective review of
existing medical records, the requirement for a formal informed
consent was waived by the IRB. Data used was de-identified to
protect patient confidentiality.
Between the inception of our lung SBRT program in 2009 and
2013, 167 patients were treated at Brigham and Women’s
Hospital/Dana-Farber Cancer Institute for peripheral lung tumors
using SBRT. From this initial data set, patients having a minimum
of one year of follow-up or a CW toxicity event were included.
The study cohort is comprised of 72 treatment plans for 69
patients. All patients in our study were treated with either 3 or 5
fractions of SBRT.
Patient clinical factors analyzed included age, gender, race,
body mass index (BMI), diabetes and smoking history. Tumor
factors included planning target volume (PTV), distance from
PTV to CW, tumor stage and histology. Smoking status was
categorized as: 1) never smokers; ,100 cigarettes in their lifetime;
2) former smokers; quit smoking .1 year prior to diagnosis, and 3)
current smokers; smoking at the time of diagnosis or had quit ,1
year prior. Treatment factors included the number of fractions
and the dose delivered to the CW determined from the CW Dose
Volume Histogram (see below).
Endpoints
As Shown in Table 1, CW toxicity was defined by the
Common Terminology Criteria for Adverse Events (CTCAE)
version 4.0, with the following modifications. Grade 1: mild pain
requiring no pain medications, Grade 2: moderate pain requiring
non-narcotic analgesics, and Grade 3: severe pain requiring
narcotic analgesics. Patients whose toxicity level changed over time
were scored at the time of greatest toxicity. For the three patients
who received two separate courses of SBRT, the CW toxicity was
scored separately for each lesion because the tumors were located
in separate lobes.
Primary tumor control and local control were defined as the
absence of primary tumor or local failure, respectively, based on
the definitions outlined in RTOG 0236. In brief, primary tumor
failure was defined as (1) local enlargement defined as at least a
20% increase in the longest diameter of the gross tumor volume
per CT scan and (2) evidence of tumor viability (either PET-CT
demonstrating FDG-uptake of similar intensity as the pretreat-
ment staging PET, or with pathologic confirmation via biopsy).
Primary tumor failure included marginal failures occurring within
1 cm of the planning target volume (1.5–2.0 cm from the gross
tumor volume). Failure beyond the primary tumor but within the
involved lobe was also ascertained and local failure was defined as
any primary tumor and/or involved lobe failure.
SBRT Treatment and Follow-up Procedure
All patients were treated with risk-adapted SBRT per institu-
tional norms, which included 1) restriction of SBRT to treat
peripheral tumors only; 2) immobilization of patients with a vac-
lock bag in a stereotactic frame; 3) use of abdominal compression
to restrict tumor motion to ,1 cm; 4) 4D-CT planning with
generation of an internal target volume (ITV) using maximum-
intensity projection and 4D cine; 5) use of a 5 mm PTV margin
with no clinical target volume (CTV) margin; 6) prescribed dose
using a risk-adapted approach of 11–12 Gy65 fractions for tumors
either in broad contact with the CW and/or with V30.30 mL,
and 18 Gy63 fractions for all other tumors; 7) treatment delivered
every other day with daily image-guidance using ExacTracH,
cone-beam CT, and portal imaging. Treatment planning for all
patients was performed using the Eclipse Treatment Planning
system (Varian Medical Systems, Palo Alto, CA) and the AAA
dose algorithm with heterogeneity corrections. The ITV was
expanded by 5 mm volumetrically to create the PTV, but
constrained from expanding into the CW. The CW was treated
as an organ at risk during plan development with particular effort
made to maintain V30,30 mL. Treatment planning methods
Table 1. CTCAEv.4 chest wall pain toxicity scale and modified chest wall toxicity scale used in the current report.
Toxicity Grade CTCAEv.4* Modified Chest Wall Toxicity Assessment for Current Study
Grade 0 No pain No pain
Grade 1 Mild pain Mild pain, requiring no pain medicines
Grade 2 Moderate pain; limiting instrumental ADL Moderate pain, requiring non-narcotic analgesics
Grade 3 Severe pain; limiting self care ADL Severe pain, requiring narcotic analgesics
doi:10.1371/journal.pone.0094859.t001
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minimize CW dose without compromising target coverage or
violating constraints on other critical organs.
Patients were seen by a physician daily during treatment and
then post-treatment, for a full history with attention to toxicity
assessment including CW injury and physical exam, every 3–4
months for the first two years, then every 6 months for the next
two years, and annually thereafter. Patients also underwent chest
CT scans on the same schedule. These were used to assess the
presence of rib fractures.
Evaluation of the chest wall dose
The CW was contoured by first expanding the lungs uniformly
by 3 cm and then subtracting lung volumes from the expanded
volume. The CW volume was then edited to remove the
mediastinum and spinal column. The remaining volume was
defined as the CW volume as shown in Figure 1.
Dose Metrics used for Statistical Analysis
We analyzed dose-volume metrics to identify predictors of CW
toxicity, including maximum CW dose, (CWmax), the minimum
dose delivered to the 2 cc of CW receiving the highest dose (D2cc).
Vx is the absolute volume of CW receiving a specified dose or
higher (V20, V30, etc… where the number after the ‘V’ is the dose
in Gy and the value is the volume in mL). e.g. V30=15 mL would
mean that 15 mL of the CW is receiving at least 30 Gy. These
values were tabulated for our analysis at dose levels from 20 to
70 Gy in 10 Gy increments.
Another dose metric we examined is the area under the curve
(AUC) of the cumulative DVH curve. This was calculated by
means of a simple integration routine for portions of the DVH
above a threshold dose level, as well as for the entire DVH curve
(threshold of zero). The AUC was calculated for threshold levels
from 0 to 70 Gy in 10 Gy increments. The principle rationale
behind the threshold value is that CW toxicity may only take effect
above some minimum dose level. The AUC metric provides a
broad measure roughly proportional to the integral dose, above
the threshold level, received by the organ.
Finally, to account for the differences in biological effectiveness
of the different fractionation schemes we calculated the modified
equivalent dose (mEUD) using in-house developed software. As
previously described by Woody et al., the mEUD was calculated
for a truncated [9] (i.e. ‘‘limited’’) CW volume containing the
100 mL of tissue receiving the highest dose, which may be more
relevant to the incidence of toxicity since only a small portion of
the CW receives high dose.
The equation for mEUD is given by:
mEUD~
P N
i~1
niDa
i 1z
di a=b
 ! "#  !
C
1
a
Where N is the total number of dose bins, di is the fractional
dose and Di is the total prescribed dose for sub-volume ni. The
dose Di and corresponding fractional sub-volume ni are readily
determined from the differential form of the dose volume
histogram. The fractional dose di is simply Di divided by the
number of fractions and a and b are the linear and quadratic
terms of the tissue-specific survival parameter, respectively. We
used an a/b ratio of 3Gy for the CW. C is a normalization factor
used to scale the result to be more easily comparable to a familiar
fractionation scheme. This is used because mEUD, like biologi-
cally effective dose (BED), tends to inflate the resulting dose value
when typical parameters are used. The normalization factor C
produces a mEUD comparable to clinically understood dose levels
[17]. The parameter ‘a’ is a tissue dependent parameter related to
the Lyman model [18] parameter ‘n’ by a=1/n. This parameter
determines the degree to which the organ responds to radiation in
a ‘parallel’ or ‘serial’ manner. For a completely parallel tissue a=1
and it approaches positive infinity for completely serial tissue.
When a=1, the mEUD becomes the mean dose over the entire
volume. Greater values of ‘a’ will place more importance on the
higher doses. Since the value of ‘a’ does not have a definitive value
for the CW, mEUD was calculated for a range of values of ‘a’
(a=1 & a=2.5–20 in steps of 2.5).
Statistical analysis
We performed univariate logistic regression to test for associ-
ations between clinical patient clinical factors, tumor character-
istics and dosimetry metrics with the endpoints of CW pain, rib
fracture and a composite endpoint of CW pain or rib fracture.
Multivariate analysis was also performed using a forward selection
process with a threshold of inclusion in the model of p=0.05. The
Kaplan-Meier method was utilized to estimate the 1 and 2-year
estimates of CW toxicity, primary tumor control, and local
control, and median time to events. A p-value of 0.05 or less was
considered to be statistically significant. Data were analyzed with
Minitab 16.2.3 statistical software (Minitab Inc.) and SAS (SAS
Institute Inc.).
Results
Patient and treatment characteristics
A summary of basic patient and treatment characteristics for the
72 treatment plans from 69 patients included in our study is shown
in Table 2. The median patient age was 76 years (range 45–88).
58 (80.5%) patients were treated with conformal treatment and 14
(19.5%) using volume modulated arc therapy (VMAT).
Tumor and dosimetric data
Table 3 summarizes the PTV and dosimetric data. The
median PTV size was 25.88 cc (range 6.71–109.44, Q1–Q3:
17.55–39.66). The median distance from the PTV to the CW was
0.00 mm (range 0–26.8, Q1–Q3: 0–3.19). The median follow up
time was 20.5 months (range 9–40 months) and 29 (40.3%)
patients had died by this time. The median CW V30 was
Figure 1. Chest wall and planning target volume (PTV) contour,
in blue and red respectively.
doi:10.1371/journal.pone.0094859.g001
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64.68 Gy (range 19.54–73.62). The median mEUD (a=1) was
53.08 Gy (range 21.05–97.44).
CW pain and/or rib fracture
A summary of CW toxicity is shown in Table 4. Six (8.3%)
patients developed CW pain, including three (4.2%) grade 1, two
(2.8%) grade 2 and one (1.4%) grade 3. Five patients developed rib
fractures, including one patient who had grade 2 chest pain and a
rib fracture. For the composite endpoint of any CW toxicity,
which included CW pain and/or rib fracture, there were a total of
10 events (13.9%). The 1- and 2-year estimates of any CW pain
were 5.6% and 11.1%, respectively. The 1- and 2-year estimates of
rib fracture were 2.8% and 9.3%, respectively. The 1- and 2-year
estimates of any CW toxicity were 8.4% and 18.1%, respectively.
The five patients who experienced rib fractures had median
maximum dose to CW of 57.37 Gy (range 54.98–71.93), median
CW_V20 of 50.62 cc (range 30.96–184.47) and a median PTV of
31.05 cc (range 8.23–78.87).
Univariate and multivariate analyses of CW toxicity
On univariate analysis, none of the clinical patient character-
istics (age, gender, race, diabetes, BMI, PTV distance to CW, PTV
size) or dosimetric variables (CW Max, CW V20-V70, mEUD,
Table 2. Patient and Treatment Characteristics for 72
peripheral lung SBRT treatment plans.
Characteristics N (n=72)% Median Range
Age 76 45–88
Gender
Male 31 41%
Female 41 56.9%
PS
0–1 47 65.3%
2 15 20.8%
3–4 10 13.9%
Race
White 64 88.9%
Black 5 6.9%
Other 3 4.2%
Smoking
Current 12 16.7%
Former 54 75.0%
Never 6 8.3%
Pack-years 50 1.5–136
BMI 25.5 16.7–41.9
Diabetes Mellitus 11 15.3%
T-stage
T1a 28 38.9%
T1b 23 31.9%
T2a 12 16.7%
T2b 1 1.4%
Tx[Metastasis from another
site*]
8 11.1%
Stage
IA 47 63.9%
IB 10 13.9%
IIA 1 1.4%
IV 15 20.8%
Histology
Adenocarcinoma 28 38.9%
Squamous Cell Carcinoma 16 22.2%
NSCLC NOS 12 16.7%
Metastasis from other
site*
8 11.1%
Clinical Diagnosis without
biopsy
6 8.3%
Other
# 2 2.8%
Number of Fractions
3 48 66.7%
5 24 33.3%
Technique
Conformal 58 80.5%
VMAT 14 19.5%
*Colorectal cancer (3), sarcoma (3), transitional cell carcinoma (1), cervical
cancer (1).
#Atypical carcinoid (1), Small cell lung cancer (1).
doi:10.1371/journal.pone.0094859.t002
Table 3. Tumor Characteristics and Dosimetry Metrics.
Characteristic Median Range
Distance PTV_CW [mm] 0.00 0–26.80
PTV [cc] 25.88 6.71–109.44
Maximum dose CW [Gy] 64.68 19.54–73.62
V20 [cc] 65.37 0–267.24
V30 [cc] 16.88 0–88.50
V40 [cc] 6.04 0–49.35
V50 [cc] 2.36 0–21.23
V60 [cc] 0.30 0–9.11
V70 [cc] 0 0–1.2
D(2cc) [Gy] 51.62 17.63–68.26
mEUD 1.0 [Gy] 53.08 21.05–97.44
mEUD 2.5 [Gy] 73.28 21.84–132.30
mEUD 5 [Gy] 103.73 23.10–207.85
mEUD 7.5 [Gy] 124.76 24.20–245.00
mEUD 10 [Gy] 139.96 25.15–266.64
mEUD 12.5 [Gy] 151.45 25.96–281.02
mEUD 15 [Gy] 161.40 26.66–291.41
mEUD 17.5 [Gy] 170.20 27.27–309.91
mEUD 20 [Gy] 176.56 27.80–309.91
AUC Total [Gy.cc] 9175.27 4258.02–23115.50
AUC 10 [Gy.cc] 2222.30 378–8029.37
AUC 20 [Gy.cc] 527.98 0–2634.94
AUC 30 [Gy.cc] 151.10 0–1158.37
AUC 40 [Gy.cc] 56.84 0–472.47
AUC 50 [Gy.cc] 13.06 0–172.49
AUC 60 [Gy.cc] 0.38 0–56.86
AUC 70 [Gy.cc] 0.00 0–1.39
doi:10.1371/journal.pone.0094859.t003
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$ 1). P-values ranged from 0.39–1.00, well above any acceptable
threshold for significance.
On multivariate analysis with forward selection, CW pain was
associated with PTV volume (Odds Ratio=1.21; 95% confidence
interval: 1.01–1.46; p=0.04), after adjusting for AUC beyond
10 Gy (or CW V20; Odds Ratio=1.00; 95% confidence interval:
0.99–1.00; p=0.12). However, the model was based on few
events, and thus, subject to over-fitting.
Primary Tumor Control and Local (Lobar) Control
There were 5 primary tumor failures, and the Kaplan-Meier
estimate of primary tumor control at 1-year was 95.0% and at 2-
years was 88.8%. There were a total of 9 primary tumor and lobar
failures, and the Kaplan-Meier estimate of local control at 1-year
was 90.7% and at 2-years was 83.0%;
Discussion
We have demonstrated that a risk-adapted lung SBRT
approach using 3 or 5 fractions based on CW V30 constraints
resulted in a low incidence of CW toxicity (8.3%). Thus, it appears
that CW toxicity from lung SBRT can be minimized with
treatment planning methods, which minimize dose to the CW and
incorporate a risk-adapted fractionation scheme in situations
where the target size and location limit the ability to reduce the
CW dose sufficiently.
Additionally, we performed a comprehensive analysis of patient
and tumors characteristics and multiple dosimetric variables,
including V30 [7–8] and mEUD [9] which have been previously
associated with CW toxicity, as well as two additional metrics,
D(2 ml) and AUC, which to our knowledge have not been
previously studied in conjunction with risk of CW toxicity for
SBRT. However, we did not demonstrate any significant
associations between risk of CW injury and any of these patient,
tumor or dosimetric variables. Thus, we were unable to identify
additional dosimetric constraints which could further reduce the
risk of CW injury in the setting of a risk-adapted 3 versus 5 fraction
lung SBRT planning approach that accounts for the CW as an
organ-at-risk and incorporates a V30 constraint. Lastly, neither
AUC10 nor V20 show any correlation with CW toxicities.
Table 5 shows a comparison of our results to four previous
studies. The first three shown in the table, Dunlap et al, Woody et al
and Stephans et al, all report substantially higher levels of CW
toxicity than our report (18.9%–32.8% vs 8.3%). It should be
noted that Woody et al and Stephans et al are both reports from the
same institution, (Cleveland Clinic) though different selection
criteria were used (fractionation scheme) in their respective studies.
None of these three studies considered the CW as an organ-at-risk
or used planning techniques to reduce the CW dose. Additionally,
the majority of patients were treated with 60 Gy in 3 fractions
without heterogeneity corrections with an approach comparable to
that described in RTOG 0236 [6].
Comparatively, in the study by Lagerwaard et al [10], the CW
was considered an organ-at-risk and a risk-adapted fractionation
scheme was used with 20 Gy63 for peripheral tumors and
12 Gy65 for peripheral tumors in close proximity to the CW.
With this risk-adapted fractionation schedule, the incidence of CW
pain (12%) was noticeably lower than that reported for the other
three series which predominantly employed a schedule of
20 Gy63.
In comparison to the Lagerwaard et al series, which employed a
risk-adapted fractionation scheme based exclusively on tumor
location, we used tumor location and added a planning criterion
for V30. As a result, we report an even lower incidence of CW
toxicity (8.3% vs 12%) which suggests that including dosimetric
factors in a risk-adapted fractionation scheme may further reduce
the risk of CW injury.
The lack of heterogeneity corrections in the prior series of CW
toxicity may have also played a factor in the differences in the
incidence of CW toxicity observed in comparison to our study.
The 20 Gy63 fraction regimen used in RTOG 0236, and for the
majority of patients in the Dunlap et al, Stephans et al and Woody
et al series, is equivalent after heterogeneity correction to the
18 Gy63 used in our series [19]. Of note, this conversion was
based on a 2009 multi-institutional study which compared plans
without heterogeneity corrections from patients treated on RTOG
0236 to the same plan, calculated using the same monitor units,
using a superposition/convolution dose algorithm with heteroge-
neity corrections. This study found significant differences in dose
between corrected and non-corrected plans and recommended
that a lower dose (18–19 Gy for 3 fractions) be used in place of
20Gy in three fractions if heterogeneity corrections are used. This
study also demonstrated that doses in normal tissues were
markedly increased and exceeded the protocol-specified con-
straints in at least a few cases after heterogeneity correction. While
CW constraints were not included in RTOG 0236, previous
studies [7–8] have clearly indicated that the risk of CW toxicity
Table 4. Incidence of Chest Wall Toxicities for 72 peripheral lung SBRT treatment plans.
Chest Wall Toxicity N (%)
Median time to toxicty
(months) Range (months) Q1–Q3 (months)
Chest Wall Pain Grade 0 66 (91.7%)
Grade 1 3 (4.2%)
Grade 2 2 (2.8%)
Grade 3 1 (1.4%)
Any Chest Wall Pain 6 (8.3%) 9.5 0–24 6.25–14.25
Rib Fracture Asymptomatic 4 (5.6%)
Symptomatic* 1 (1.4%)
Any Rib Fracture 5 (6.9%) 14 2–21 3–17
Any Chest Wall Toxicity 10 (13.9%) 9.5 0–24 3–15
*Grade 2 pain.
doi:10.1371/journal.pone.0094859.t004
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exceeds a given threshold. Thus, the greater accuracy of a
heterogeneity corrected dose calculation may reveal high dose
areas in the CW, which can potentially be reduced by plan
optimization, which would not be shown if corrections were not
used.
Limitations of this study include the retrospective design, and
the lack of patient reported outcomes. Additionally, given the
small number of CW toxicity events, our study may be
underpowered to detect further associations between CW toxicity
and the clinical and dosimetric variables included in our univariate
analyses. Thus, additional clinical and dosimetric constraints,
which may be important after controlling for V30 in the planning
process and with risk-adapted fractionation, could still be
identified with further study in a larger series with a larger
number of total events.
In summary, risk-adapted fractionation that incorporates CW
V30 constraints results in a low incidence of CW toxicity, and we
did not identify any additional patient, tumor or dosimetric
variables that predict for CW toxicity.
Conclusion
Risk-adapted fractionation based on tumor and dosimetric
factors can be used for lung SBRT treatments and results in a low
incidence of CW toxicity. The treatment methods used at our
institution have been shown to produce a lower rate of CW pain
for lung SBRT patients than previously reported in the literature.
A thorough analysis of patient, tumor and dosimetric variables for
potential predictors of CW toxicity did not identify any statistically
significant associations. We conclude that our planning methods
are associated with a low risk of CW toxicity. At present, there are
no apparent dosimetric parameters to pursue for further reduction
of the incidence of CW pain, but with continued study, relevant
parameters may be identified.
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